Eyes on New Product Development

Kubota R. , Calkins D.J. , Henry S.H. , and Linsenmeier R.A. Emixustat reduces metabolic demand of dark activity in the retina. Invest. Ophthalmol. Vis. Sci. 60:4924–4930, 2019.

Bartlett V.L. , Dhruva S.S. , Shah N.D. , Ryan P. , and Ross J.S. Feasibility of using real-world data to replicate clinical trial evidence. JAMA Netw. Open, 2:e1912869, 2019.

Novack G.D. Pipeline: real world evidence for pharmaceuticals. Ocul Surf, 17:584–588, 2019.

Björk B.-C. , Kanto-Karvonen S. , and Harviainen J.T. How frequently are articles in predatory open access journals cited. arXiv arXiv:191210228 2019.

Brainard J. Articles in ‘predatory’ journals receive few or no citations. Science, 367:129, 2020.

DiMasi J.A. , Florez M.I. , Stergiopoulos S. , et al. Development times and approval success rates for drugs to treat infectious diseases. Clin. Pharmacol. Ther. 107:324–332, 2020.

Barnett B. The 90-day prescription isn't for everyone. Wall Street J. February 7, 2020.

Piller C. Transparency on trial. Science, 367:240–243, 2020.

Anonymous. Agency information collection activities; proposed collection; comment request; empirical study of promotional implications of proprietary prescription drug names. Fed. Regist. 85:3392–3394, 2020.